Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1704 DOS neoadjuvant chemotherapy for advanced gastric cancer with extensive lymph node metastasis
jRCTs031180028Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and tegafur in gastric cancer (GC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Pathological response rate. Started Dec 2018; status: active, not recruiting.
02
Drugs
docetaxeloxaliplatintegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs031180028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180028.